VivoSeq
Gastroenterology

Primary Biliary Cirrhosis

37

Pipeline Programs↗

1

Active Trials↗

24

Companies Involved↗

Primary Biliary Cirrhosis is a moderately active landscape with 37 programs across 24 companies. The most active players are Prism Pharmaceuticals, Roche, Daewoong Pharmaceutical Co. LTD.. 6 therapies are approved with 14 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

55/100

Pipeline Velocity

0/100

Mech. Concentration

10/100

Completion Rate

77/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Prism Pharmaceuticals

1 program

Phase 1Roche logo

Roche

1 program

Phase 1Daewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.

1 program

Phase 1M

Mirum Pharmaceuticals, Inc.

1 program

Phase 2N

NGM Biopharmaceuticals, Inc

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

36 of 41 classified programs — the dominant modality here.

12%ALL OTHERSMonoclonal antibody25%Cell therapy25%Protein / enzyme12%

Small molecule leads; the ring shows all 41 classified programs, each share of the total. Modality classified for 98% of 43 pipeline programs.

Analysis

Trial Status

41

clinical trials

Completed27 · 66%
Unknown status5 · 12%
Terminated4 · 10%
Withdrawn4 · 10%
Active, not recruiting1 · 2%

Clinical Trials

Trial Activity

41 trials

A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid
Active, not recruiting·Ipsen logoIpsen·Phase 3·NCT04526665·161 enrolled
Phase III Randomized Study of Ursodiol With Vs Without Methotrexate for Primary Biliary Cirrhosis
Completed·NNational Center for Research Resources (NCRR)·Phase 3·NCT00004784·315 enrolled
Ursodiol-Methotrexate for Primary Biliary Cirrhosis
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT00006168
B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis
Completed·NNewcastle-upon-Tyne Hospitals NHS Trust·Phase 2·NCT02376335·71 enrolled
A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT01389973·20 enrolled
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus
Completed·GSK logoGSK·Phase 2·NCT01899703·22 enrolled
Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis
Completed·MMirum Pharmaceuticals, Inc.·Phase 2·NCT01904058·66 enrolled
Pentoxifylline for Primary Biliary Cirrhosis
Completed·TThe Cleveland Clinic·Phase 2·NCT01249092·20 enrolled
Moexipril for Primary Biliary Cirrhosis
Completed·MMayo Clinic·Phase 2·NCT00588302·20 enrolled
Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis (PBC)
Completed·MMayo Clinic·Phase 1·NCT00943176·40 enrolled
Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis
Completed·—·Phase 4·NCT02078882·16 enrolled
Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary Cirrhosis
Completed·SShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.·Phase 3·NCT06715319·100 enrolled
Safety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary Cirrhosis
Completed·MMedical University of Graz·Phase 3·NCT00844402·40 enrolled
Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis
Completed·XXijing Hospital of Digestive Diseases·Phase 3·NCT02823353·117 enrolled
Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis
Completed·NNational Center for Research Resources (NCRR)·Phase 3·NCT00004748·90 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)